NCT07509684 2026-04-13
A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Chengdu Kanghong Biotech Co., Ltd.